Legend Biotech Company Growth, Stability & Outlook

Key Insight for Candidates

• Strong Market Position & Advantage: Carvykti is positioned as the first and only BCMA‑targeted therapy approved as early as second line in the U.S./EU with overall‑survival data reflected on label, and commercial uptake has outpaced Abecma in the BCMA CAR‑T segment. Market updates cite thousands of patients treated and describe the product as a current standard‑setter within BCMA CAR‑T for multiple myeloma.
• Strong Revenue Growth: Revenue and CARVYKTI sales have scaled rapidly through 2024–2025, with FY2024 revenue roughly $627M (up sharply year over year) and CARVYKTI net trade sales around $963M in 2024 followed by sequential increases in 2025. Collaboration revenue tied to CARVYKTI also rose significantly as availability and demand expanded.
• Strategic Partnerships: The J&J collaboration underpins global development and commercialization while additional manufacturing collaboration with Novartis and capacity build‑outs in Belgium and the U.S. support supply. A licensing deal with Novartis for a DLL3 CAR‑T program further validates the platform and broadens modality reach.

• Undiversified Revenue Streams: Growth is heavily reliant on a single commercial asset (CARVYKTI), creating concentration risk. Any manufacturing, safety, or access disruption would disproportionately impact financial performance.
• Operational Inefficiency: Manufacturing capacity, site onboarding, and scheduling have periodically constrained supply and created quarter‑to‑quarter variability. CAR‑T’s vein‑to‑vein logistics and class‑wide safety management add operational complexity that can cap near‑term revenue.
• Declining Profitability: The company remained loss‑making across several periods (e.g., a net loss in Q3 2025) despite rapid top‑line growth. Management’s profitability timeline depends on continued scale‑up and efficiency gains to offset costs.